ArticleOrphanet journal of rare diseases2010
Rituximab ameliorated severe hearing loss in Cogan's syndrome: a case report.
Article in Orphanet journal of rare diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Secondary autoimmune immune ear disease (AIED): a systematic review and meta-analysis on vestibular manifestations of systemic autoimmune and inflammatory disorders.Clinical rheumatology · 2023Pooled it
- COGAN'S SYNDROME.Romanian journal of ophthalmologyPooled it
- Cogan's syndrome is more than just keratitis: a case-based literature review.BMC ophthalmology · 2023Article
- Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab.Internal medicine (Tokyo, Japan) · 2022Article
- Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022Review
- Pathophysiology and therapy of systemic vasculitides.EXCLI journal · 2020Review
- Emerging options in immune-mediated hearing loss.Laryngoscope investigative otolaryngology · 2019Review
- Autoimmune Inner Ear Disease: Immune Biomarkers, Audiovestibular Aspects, and Therapeutic Modalities of Cogan's Syndrome.Journal of immunology research · 2018Review
- Optimal management of Cogan's syndrome: a multidisciplinary approach.Journal of multidisciplinary healthcare · 2018Review
- Rituximab Not Effective for Hearing Loss in Cogan's Syndrome.Case reports in rheumatology · 2016Article
- Cogan's syndrome--clinical guidelines and novel therapeutic approaches.Clinical reviews in allergy & immunology · 2014Review
- New prospects in the diagnosis and treatment of immune-mediated inner ear disease.World journal of methodology · 2014Review
- Atypical Cogan's Syndrome Presenting as Anterior Scleritis: Case Report.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRituximab is a monoclonal antibody inducing depletion of B lymphocytes and presently approved for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. Here is the first report of the use of this drug in a case of Cogan's syndrome (CS). CASE PRESENTATION: a 25-year-old Italian woman was referred with conjunctival hyperaemia, interstitial keratitis, moderate bilateral sensorineural hearing loss accompanied by tinnitus, dizziness, nausea and vertigo, poorly responsive to oral and topical steroidal therapy. Diagnosis of typical CS was made. The administration of a combined immunosuppressive treatment resolved ocular inflammation, dizziness, nausea, and vertigo but gave little results in controlling progressive hearing loss. A noticeable improvement in hearing function was documented by pure tone audiometry after infusion of Rituximab. DISCUSSION: in CS, hearing function is often the most difficult parameter to control with therapy. A positive effect of Rituximab on was observed in our case. The drug also allowed to significantly reduce the number of adjuvant immunosuppressive medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.